Research programme: interleukin-4/5 secretion inhibitors - Fournier/Zambon
Alternative Names: IL-4/5 secretion inhibitors - Fournier/ZambonLatest Information Update: 14 Aug 2007
At a glance
- Originator Laboratoires Fournier; Zambon Group SpA
- Developer Zambon Group SpA
- Class
- Mechanism of Action Cytokine inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypersensitivity; Respiratory tract disorders
Most Recent Events
- 29 Jul 2004 This programme is still in active development
- 02 May 2002 Preclinical trials in Allergy in Switzerland (unspecified route)
- 02 May 2002 Preclinical trials in Respiratory tract disorders in Switzerland (unspecified route)